Changes in weight and BMI with first-line doravirine-based therapy.

ABSTRACT:

Objective

To evaluate changes in weight and BMI in adults with HIV-1 at 1 and 2 years after starting an antiretroviral regimen that included doravirine, ritonavir-boosted darunavir, or efavirenz.

Design

Post-hoc analysis of pooled data from three randomized controlled trials.

Methods

We evaluated weight change from baseline, weight gain at least 10%, and increase in BMI after 48 and 96 weeks of treatment with doravirine, ritonavir-boosted darunavir, or efavirenz-based regimens. Risk factors for weight gain and metabolic outcomes associated with weight gain were also examined.

Results

Mean (and median) weight changes were similar for doravirine [1.7 (1.0) kg] and ritonavir-boosted darunavir [1.4 (0.6) kg] and were lower for efavirenz [0.6 (0.0) kg] at week 48 bu

SUBMITTER: Orkin C 

PROVIDER: S-EPMC7752237 | biostudies-literature | 2021 Jan

REPOSITORIES: biostudies-literature